<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625871</url>
  </required_header>
  <id_info>
    <org_study_id>vivax</org_study_id>
    <nct_id>NCT01625871</nct_id>
  </id_info>
  <brief_title>Artemether/Lumefantrine and Vivax Malaria</brief_title>
  <official_title>Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Khartoum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kassala, Sudan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Khartoum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The cure rate of artemether/lumefantrine in the treatment of vivax malaria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cure rate</measure>
    <time_frame>28 days</time_frame>
    <description>The proportion of the cure patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever clearance time</measure>
    <time_frame>28 days</time_frame>
    <description>The time for fever clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parasite clearance time</measure>
    <time_frame>28 days</time_frame>
    <description>The time for the parasite to clear</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Vivax Malaria</condition>
  <arm_group>
    <arm_group_label>artemether-lumefantrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets (containing 20mg artemether and 120 mg lumefantrine) for three days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tablets artemether/lumefantrine</intervention_name>
    <description>six doses of oral tablets of artemether/lumefantrine</description>
    <arm_group_label>artemether-lumefantrine</arm_group_label>
    <other_name>Quartem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with vivax malaria

        Exclusion Criteria:

          -  severe malaria

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kassala</name>
      <address>
        <city>Kassala</city>
        <zip>249</zip>
        <country>Sudan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed?term=adam%20i</url>
    <description>http://www.ncbi.nlm.nih.gov/pubmed?term=adam%20i</description>
  </link>
  <reference>
    <citation>Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5. doi: 10.1186/1475-2875-8-S1-S5. Review.</citation>
    <PMID>19818172</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2012</study_first_submitted>
  <study_first_submitted_qc>June 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2012</study_first_posted>
  <last_update_submitted>January 16, 2013</last_update_submitted>
  <last_update_submitted_qc>January 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Khartoum</investigator_affiliation>
    <investigator_full_name>Ishag Adam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>malaria</keyword>
  <keyword>vivax</keyword>
  <keyword>artemether/lumefantrine</keyword>
  <keyword>Sudan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Vivax</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 5, 2013</submitted>
    <returned>April 15, 2013</returned>
    <submitted>April 19, 2013</submitted>
    <returned>May 23, 2013</returned>
    <submitted>May 27, 2013</submitted>
    <returned>May 28, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

